Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients

Inclusion Criteria: 1. Patients with clinical diagnosis of moderate to severe facial rosacea as determined by: * At least 8 but no more than 50 total papules and/or pustules (inflammatory lesions) * Presence of moderate to severe erythema * Presence of telangiectasia. * An Overall Rosacea Severity score ≥2.5 2. Patient is male or female over 18 years of age. 3. No known medical conditions that, in the Investigator's opinion could interfere with study participation 4. Patient is willing and able to comply with all requirement of the protocol 5. Patient is willing and able to give written informed consent prior to participation in the study Exclusion Criteria: 1. Presence of skin diseases at or near the investigational area 2. Immunosuppressed state or other serious systemic disease 3. Signs and/or symptoms of systemic infection 4. Concomitant medication: * Use of oral and/or topical antibiotic treatment within 14 days prior to study entry. * Use of any topical anti-rosacea agent except antibiotics within 14 days prior to study entry. * Use of cyproterone acetate, CPA-containing contraceptives (e.g. Diane) or other corticosteroids (during the last 3 months); * Use of retinoids (during the last 4 weeks) 5. Use of artificial sun bath or having a sun holiday during the last 2 weeks 6. Alcohol or drug abuse, according to assessment by the investigator 7. Known or suspected hypersensitivity to Minocycline or any of the excipients in the Study Medication 8. Use of another investigational drug within 30 days prior to entry into this study 9. Pregnant or lactating women.